A share price of Avadel Pharmaceuticals plc [AVDL] is currently trading at $9.09, up 12.08%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AVDL shares have gain 14.05% over the last week, with a monthly amount drifted -14.97%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avadel Pharmaceuticals plc [NASDAQ: AVDL] stock has seen the most recent analyst activity on June 12, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $27. Previously, Oppenheimer reaffirmed its Outperform rating on March 05, 2024, and elevated its price target to $29. On March 05, 2024, Needham reiterated its Buy rating and revised its price target to $22 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $25 on March 05, 2024. UBS initiated its recommendation with a Buy and recommended $21 as its price target on February 06, 2024. Jefferies upgraded its rating to Buy for this stock on November 30, 2022, and upped its price target to $11. In a note dated August 10, 2022, Jefferies downgraded an Hold rating on this stock and boosted its target price from $6 to $8.
Avadel Pharmaceuticals plc experienced fluctuations in its stock price throughout the past year between $7.39 and $19.09. Currently, Wall Street analysts expect the stock to reach $23.33 within the next 12 months. Avadel Pharmaceuticals plc [NASDAQ: AVDL] shares were valued at $9.09 at the most recent close of the market. An investor can expect a potential return of 156.66% based on the average AVDL price forecast.
Analyzing the AVDL fundamentals
Trailing Twelve Months sales for Avadel Pharmaceuticals plc [NASDAQ:AVDL] were 138.16M which represents 613.22% growth. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.46%, Pretax Profit Margin comes in at -0.53%, and Net Profit Margin reading is -0.53%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.93 and Total Capital is -0.55. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.34 points at the first support level, and at 7.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.50, and for the 2nd resistance point, it is at 9.91.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Avadel Pharmaceuticals plc [NASDAQ:AVDL] is 2.97. In addition, the Quick Ratio stands at 2.60 and the Cash Ratio stands at 0.67. Considering the valuation of this stock, the price to sales ratio is 6.34, the price to book ratio is 11.73.
Transactions by insiders
Recent insider trading involved Palczuk Linda, Director, that happened on Jan 21 ’25 when 5000.0 shares were purchased. Director, Thornton Peter J. completed a deal on Jan 13 ’25 to buy 10000.0 shares. Meanwhile, Director Ende Eric J bought 30000.0 shares on Jan 13 ’25.
